Abstract
Eight loci have been identified by the two genome-wide association studies of Barrett’s esophagus that have been conducted to date. Esophageal adenocarcinoma cases were included in the second study following evidence that predisposing genetic variants for this cancer overlap with those for Barrett’s esophagus. Genes with roles in embryonic development of the foregut are adjacent to 6 of the loci identified (FOXF1, BARX1, FOXP1, GDF7, TBX5, and ALDH1A2). An additional locus maps to a gene with known oncogenic potential (CREB-regulated transcription coactivator 1), but expression quantitative trait data implicates yet another gene involved in esophageal development (PBX4). These results strongly support a model whereby dysregulation of genes involved in esophageal and thoracic development increases susceptibility to Barrett’s esophagus and esophageal adenocarcinoma, probably by reducing anatomical antireflux mechanisms. An additional signal at 6p21 in the major histocompatibility complex also reinforces evidence that immune and inflammatory response to reflux is involved in the development of both diseases. All of the variants identified are intronic or intergenic rather than coding and are presumed to be or to mark regulatory variants. As with genome-wide association studies of other diseases, the functional variants at each locus are yet to be identified and the genes affected need confirming. In this chapter as well as discussing the biology behind each genome-wide association signal, we review the requirements for successfully conducting genome-wide association studies and discuss how progress in understanding the genetic variants that contribute to Barrett’s esophagus/esophageal adenocarcinoma susceptibility compares to other cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Barrett N. Chronic peptic ulcer of the oesophagus and “oesophagitis”. Br J Surg. 1950;38:175–82.
Watson A, Heading RC, Shepherd NA. Guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus. A report of the Working Party of the British Society of Gastroenterology. 2005. http://www.bsg.org.uk.
Cameron AJ, Lomboy CT. Barrett’s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103(4):1241–5.
Ronkainen J, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–31.
Cameron AJ, et al. Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99(4):918–22.
Hvid-Jensen F, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.
Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003;3(9):676–84.
Mistry M, et al. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105(11):1795–803.
Rutegard M, et al. Population-based esophageal cancer survival after resection without neoadjuvant therapy: an update. Surgery. 2012;152(5):903–10.
Davies AR, et al. Factors associated with early recurrence and death after esophagectomy for cancer. J Surg Oncol. 2014;109(5):459–64.
Gerson LB, et al. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96(7):2005–12.
Sharma P, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392–9.
Chak A, et al. Familiality in Barrett’s esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1668–73.
Verbeek RE, et al. Familial clustering of Barrett’s esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol. 2014;12(10):1656–63. e1.
Trudgill NJ, Kapur KC, Riley SA. Familial clustering of reflux symptoms. Am J Gastroenterol. 1999;94(5):1172–8.
Sappati Biyyani RS, et al. Familial trends of inheritance in gastro esophageal reflux disease, Barrett’s esophagus and Barrett’s adenocarcinoma: 20 families. Dis Esophagus. 2007;20(1):53–7.
Mohammed I, et al. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut. 2003;52(8):1085–9.
Sun X, et al. A segregation analysis of Barrett’s esophagus and associated adenocarcinomas. Cancer Epidemiol Biomarkers Prev. 2010;19(3):666–74.
Bodmer WF. Mutations of the APC (adenomatous polyposis coli) gene in human cancers. Jpn J Cancer Res. 1994;85(6): p. inside front cover.
Lindblom A, et al. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet. 1993;5(3):279–82.
Peltomaki P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993;260(5109):810–2.
Orloff M, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011;306(4):410–9.
Babar M, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2012;107(9):1331–41.
Bradbury PA, et al. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 2009;30(5):793–8.
Casson AG, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730–9.
di Martino E, et al. The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med. 2007;9(6):341–7.
Gough MD, et al. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important? Am J Gastroenterol. 2005;100(5):1012–8.
Izakovicova Holla L, et al. Haplotypes of the IL-1 gene cluster are associated with gastroesophageal reflux disease and Barrett’s esophagus. Hum Immunol. 2013;74(9):1161–9.
Kala Z, et al. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett’s esophagus. J Hum Genet. 2007;52(6):527–34.
MacDonald K, et al. A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma. Cancer Epidemiol. 2009;33(1):37–40.
McElholm AR, et al. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology. 2010;139(1):204–12. e3.
Menke V, et al. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett’s esophagus and esophageal adenocarcinoma. J Hum Genet. 2012;57(1):26–32.
Menke V, et al. NcoI TNF-beta gene polymorphism and TNF expression are associated with an increased risk of developing Barrett’s esophagus and esophageal adenocarcinoma. Scand J Gastroenterol. 2012;47(4):378–86.
Menke V, et al. Myo9B is associated with an increased risk of Barrett’s esophagus and esophageal adenocarcinoma. Scand J Gastroenterol. 2012;47(12):1422–8.
Moons LM, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. Carcinogenesis. 2008;29(5):926–31.
van de Winkel A, et al. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett’s esophagus and esophageal adenocarcinoma. BMC Gastroenterol. 2011;11:108.
van Lieshout EM, et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett’s esophagus and esophageal carcinoma. Cancer Res. 1999;59(3):586–9.
Palles C, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus. Gastroenterology. 2015;148(2):367–78.
Su Z, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet. 2012;44(10):1131–6.
Levine DM, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet. 2013;45(12):1487–93.
Chakravarti A. Population genetics—making sense out of sequence. Nat Genet. 1999;21(1 Suppl):56–60.
Lander ES. The new genomics: global views of biology. Science. 1996;274(5287):536–9.
Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene. 2004;23(38):6471–6.
International HapMap Consortium. The International HapMap project. Nature. 2003;426(6968):789–96.
Oliphant A, et al. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques 2002(Suppl):56-8, 60-1.
Michailidou K, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61. 361e1-2.
Spencer CC, et al. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 2009;5(5):e1000477.
Turner S, et al. Quality control procedures for genome-wide association studies. Curr Protoc Hum Genet. 2011. Chapter 1:Unit1 19.
Weale ME. Quality control for genome-wide association studies. Methods Mol Biol. 2010;628:341–72.
Winkler TW, et al. Quality control and conduct of genome-wide association meta-analyses. Nat Protoc. 2014;9(5):1192–212.
Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–9.
Altshuler DM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.
Wessel J, et al. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun. 2015;6:5897.
Zuo X, et al. Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis. Nat Commun. 2015;6:6793.
Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1(6):457–70.
Whiffin N, et al. Deciphering the genetic architecture of low-penetrance susceptibility to colorectal cancer. Hum Mol Genet. 2013;22(24):5075–82.
Kreiner-Moller E, et al. Improving accuracy of rare variant imputation with a two-step imputation approach. Eur J Hum Genet. 2015;23(3):395–400.
French JD, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet. 2013;92(4):489–503.
Amos CI, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011;20(24):5012–23.
Abnet CC, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 2010;42(9):764–7.
Dura P, et al. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer. 2013;133(7):1751–5.
Lan Q, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012;44(12):1330–5.
Chen D, et al. Genome-wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst. 2013;105(9):624–33.
Lu CC, et al. Nasopharyngeal carcinoma-susceptibility locus is localized to a 132 kb segment containing HLA-A using high-resolution microsatellite mapping. Int J Cancer. 2005;115(5):742–6.
Findlay JM, Maynard ND. Pathophysiology and investigation of gastro-oesophageal reflux disease. In: Griffin SM, Raimes SA, Shenfine J, editors. Oesophagogastric surgery. Philadelphia, PA: Saunders/Elsevier; 2013.
Souza RF, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137(5):1776–84.
Rieder F, et al. Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology. 2007;132(1):154–65.
Tomita R, et al. Physiological studies on nitric oxide in the lower esophageal sphincter of patients with reflux esophagitis. Hepatogastroenterology. 2003;50(49):110–4.
Cheng L, et al. Inflammation induced changes in arachidonic acid metabolism in cat LES circular muscle. Am J Physiol Gastrointest Liver Physiol. 2005;288(4):G787–97.
Eastwood GL, et al. Beneficial effect of indomethacin on acid-induced esophagitis in cats. Dig Dis Sci. 1981;26(7):601–8.
Boderg K, Trudgill H. Guidelines for oesophageal manometry and pH monitoring. British Society of Gastroenterology: Guidelines in Gastroenterology; 200.
O’Riordan JM, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100(6):1257–64.
Tselepis C, et al. Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. Oncogene. 2002;21(39):6071–81.
Montgomery SB, et al. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature. 2010;464(7289):773–7.
Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett. 1995;93(1):17–48.
Wu C, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet. 2012;44(10):1090.
Yoshida A, Hsu LC, Yasunami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res Mol Biol. 1991;40:255–87.
Yin SJ, et al. Polymorphism of human liver alcohol dehydrogenase: identification of ADH2 2-1 and ADH2 2-2 phenotypes in the Japanese by isoelectric focusing. Biochem Genet. 1984;22(1–2):169–80.
Fang JL, Vaca CE. Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. Carcinogenesis. 1997;18(4):627–32.
Wang XD, et al. Chronic alcohol intake reduces retinoic acid concentration and enhances AP-1 (c-Jun and c-Fos) expression in rat liver. Hepatology. 1998;28(3):744–50.
Osanai M, Lee GH. Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes. 2014;7:697.
Freedman ND, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011;60(8):1029–37.
Rhinn M, Dolle P. Retinoic acid signalling during development. Development. 2012;139(5):843–58.
Pavlov K, et al. Embryological signaling pathways in Barrett’s metaplasia development and malignant transformation; mechanisms and therapeutic opportunities. Crit Rev Oncol Hematol. 2014;92(1):25–37.
Mahlapuu M, Enerback S, Carlsson P. Haploinsufficiency of the forkhead gene Foxf1, a target for sonic hedgehog signaling, causes lung and foregut malformations. Development. 2001;128(12):2397–406.
Hoffmann AD, et al. Foxf genes integrate tbx5 and hedgehog pathways in the second heart field for cardiac septation. PLoS Genet. 2014;10(10):e1004604.
Szafranski P, et al. Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins. Am J Med Genet A. 2014;164A(8):2013–9.
Arora R, Metzger RJ, Papaioannou VE. Multiple roles and interactions of Tbx4 and Tbx5 in development of the respiratory system. PLoS Genet. 2012;8(8):e1002866.
Smemo S, et al. Regulatory variation in a TBX5 enhancer leads to isolated congenital heart disease. Hum Mol Genet. 2012;21(14):3255–63.
Berasi SP, et al. Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 independent of receptor binding affinities. Growth Factors. 2011;29(4):128–39.
Lo L, Dormand EL, Anderson DJ. Late-emigrating neural crest cells in the roof plate are restricted to a sensory fate by GDF7. Proc Natl Acad Sci U S A. 2005;102(20):7192–7.
Takata R, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751–4.
Ek WE, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett’s esophagus, and gastroesophageal reflux. J Natl Cancer Inst. 2013;105(22):1711–8.
Woo J, et al. Barx1-mediated inhibition of Wnt signaling in the mouse thoracic foregut controls tracheo-esophageal septation and epithelial differentiation. PLoS One. 2011;6(7):e22493.
Shu W, et al. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development. 2007;134(10):1991–2000.
Banham AH, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001;61(24):8820–9.
Elks CE, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet. 2010;42(12):1077–85.
Komiya T, et al. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene. 2006;25(45):6128–32.
Gu Y, et al. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene. 2012;31(4):469–79.
Lettice LA, et al. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet. 2003;12(14):1725–35.
Diiorio P, et al. TALE-family homeodomain proteins regulate endodermal sonic hedgehog expression and pattern the anterior endoderm. Dev Biol. 2007;304(1):221–31.
Weaver JM, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014;46(8):837–43.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Palles, C., Findlay, J.M., Tomlinson, I. (2016). Common Variants Confer Susceptibility to Barrett’s Esophagus: Insights from the First Genome-Wide Association Studies. In: Jansen, M., Wright, N. (eds) Stem Cells, Pre-neoplasia, and Early Cancer of the Upper Gastrointestinal Tract. Advances in Experimental Medicine and Biology, vol 908. Springer, Cham. https://doi.org/10.1007/978-3-319-41388-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-41388-4_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41386-0
Online ISBN: 978-3-319-41388-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)